Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Immunotherapy Gastrict Cancer × apatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 5 Stomach Neoplasms 4 Carcinoma, Non-Small-Cell Lung 2 Breast Neoplasms 2 Osteosarcoma 1 Neoplasm Metastasis 1 Immunotherapy Gastrict Cancer 1 Esophageal Neoplasms 1 Adenocarcinoma 1

Interventions

tislelizumab 1 apatinib 1 S 1 (combination) 1 Oxaliplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05699655 2024-05-01

Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

Fujian Cancer Hospital

Phase 2/3 Recruiting

Gastrointestinal

Immunotherapy Gastrict Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡